<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645251</url>
  </required_header>
  <id_info>
    <org_study_id>228220</org_study_id>
    <nct_id>NCT04645251</nct_id>
  </id_info>
  <brief_title>Polycystic Liver Disease Registry (UK)</brief_title>
  <acronym>PLD</acronym>
  <official_title>Polycystic Liver Disease Registry (UK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portsmouth Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Portsmouth Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre, observational registry studying the natural course of polycystic liver disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Polycystic Liver Disease (PLD) registry (UK) is the UK specific part of an international,&#xD;
      multicentre, observational registry. The overall international PLD registry is led by Radboud&#xD;
      University Medical Center, Nijmegan, Netherlands. Note- please direct any queries about the&#xD;
      international registry to the team at Radboud University Medical Center.&#xD;
&#xD;
      All patients with Polycystic Kidney Disease (PKD) with PLD or patients with Isolated (without&#xD;
      PKD) Polycystic Liver Disease are eligible for inclusion (&gt;10 liver cysts).&#xD;
&#xD;
      Data will be collected prospectively and retrospectively including a specific validated PLD&#xD;
      questionnaire (PLD-Q).&#xD;
&#xD;
      This registry provides us insight in patient characteristics, risk factors, symptoms, quality&#xD;
      of life and treatment strategies in the biggest international PLD cohort so far. Results of&#xD;
      this registry will be published and shared at national and international congresses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Map the natural course of PLD</measure>
    <time_frame>10 years</time_frame>
    <description>To establish the demographics, presence and severity of symptoms (quantified using the validated PLD-Q questionnaire), liver cyst characteristics on imaging (assessed using Qian's classification), biochemical marker abnormalities (including gamma-glutamyl transferase and alkaline phosphatase), rate and nature of complications, need for treatment, change in liver volume in patients with PLD. This data will be collected retrospectively and prospectively from clinical records and the PLD-Q questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess quality of life using the validated PLD questionnaire (PLD-Q)</measure>
    <time_frame>10 years</time_frame>
    <description>The PLD-Q questionnaire consists of 18 items assessing symptom frequency and severity. It gives a score (0-100) based on the patient's answers with a higher score indicating more severe, symptomatic disease with a poorer quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elucidate risk factors for developing a complication in PLD</measure>
    <time_frame>10 years</time_frame>
    <description>For patients that develop a complication of PLD (including jaundice, abdominal hernia, features of portal hypertension, cyst haemorrhage and cyst infection) we will look through their clinical record to establish if there any risk factors which are common to those with a complication (e.g. age, gender, medications, cyst phenotype).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elucidate elements that affect PLD progression</measure>
    <time_frame>10 years</time_frame>
    <description>For patients that have a worsening of their PLD (based on increasing symptoms as per the PLD-Q questionnaire, development of complications or need for treatment) we will look through their clinical records to establish if there any elements which are common to those with progressive disease (e.g. age, gender, medications).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare effectiveness of different therapies</measure>
    <time_frame>10 years</time_frame>
    <description>For patients who have had or require treatment for PLD we will compare the effectiveness of that treatment based on change in symptoms (based on PLD-Q questionnaire), recurrence of symptoms, development of complications or need for further treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine whether rate of liver growth can be used to predict disease progression</measure>
    <time_frame>10 years</time_frame>
    <description>Liver growth rate will be determined using change in liver volume on serial radiology imaging. This will be compared against patients symptoms (measured via PLD-Q questionnaire), development of complications and need for treatment to establish whether there is a correlation in rate of liver growth and disease progression</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Mixture of adult patients with PKD and PLD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with PLD with more than 10 liver cysts&#xD;
&#xD;
          -  Patients with PKD and PLD with more than 10 liver cysts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with PKD or PLD with less than 10 liver cysts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Aspinall, BSc, MBChB, PhD</last_name>
    <phone>02392286255</phone>
    <email>richard.aspinall@porthosp.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Giles, BSc, MBBS</last_name>
    <phone>02392286000</phone>
    <phone_ext>3154</phone_ext>
    <email>benjamin.giles@porthosp.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thijs RM Barten</last_name>
      <email>thijs.rm.barten@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Joost PH Drenth</last_name>
      <email>joostphdrenth@cs.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Portmouth Hospitals University NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO63LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Giles</last_name>
      <email>benjamin.giles@porthosp.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Richard Aspinall</last_name>
      <email>richard.aspinall@porthosp.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Neijenhuis MK, Gevers TJ, Hogan MC, Kamath PS, Wijnands TF, van den Ouweland RC, Edwards ME, Sloan JA, Kievit W, Drenth JP. Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. Hepatology. 2016 Jul;64(1):151-60. doi: 10.1002/hep.28545. Epub 2016 Apr 15.</citation>
    <PMID>26970415</PMID>
  </reference>
  <reference>
    <citation>van Aerts RMM, van de Laarschot LFM, Banales JM, Drenth JPH. Clinical management of polycystic liver disease. J Hepatol. 2018 Apr;68(4):827-837. doi: 10.1016/j.jhep.2017.11.024. Epub 2017 Nov 24. Review.</citation>
    <PMID>29175241</PMID>
  </reference>
  <reference>
    <citation>Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shub C, Davila S, Somlo S, Torres VE. Clinical profile of autosomal dominant polycystic liver disease. Hepatology. 2003 Jan;37(1):164-71.</citation>
    <PMID>12500201</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymised participant data will be shared with research team at Radboud University Medical Center, Nijmegen, Netherlands.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Anonymised data will be stored for 15 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

